Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trial

Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trial

Summary: Background: The enterovirus 71 (EV71) vaccine produced by Wuhan Institute of Biological Products Co., Ltd. (WIBP) (B-EV71) has been given to children aged 6-35 months, and it has shown good safety, immunogenicity and efficacy. However, the administration of EV71 vaccine in children aged 36...

Full description

Bibliographic Details
Main Authors: Yeqing Tong, Xinyue Zhang, Jinhua Chen, Wei Chen, Zhao Wang, Qiong Li, Kai Duan, Sheng Wei, Beifang Yang, Xiaoai Qian, Jiahong Li, Lianju Hang, Shaoyong Deng, Xinguo Li, Changfu Guo, Heng Shen, Yan Liu, Peng Deng, Tingbo Xie, Qingliang Li, Li Li, Hongqiao Du, Qunying Mao, Fan Gao, Weiwei Lu, Xuhua Guan, Jiao Huang, Xiuling Li, Xiaoqi Chen
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:EClinicalMedicine
Subjects:
Enterovirus 71 vaccine
Hand, foot and mouth disease
Immunogenicity
Safety
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022003261

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022003261

Similar Items